EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Other Sources: 6

Resistant starch

Also called: RS, type 2 resistant starch (RS2), high-amylose maize starch, high-amylose corn starch, RS4

Starch counted among non-digestible carbohydrates: FDA lists high-amylose starch (resistant starch 2) and cross-linked phosphorylated RS4 among fibers it intends to propose for the dietary fiber definition. Type 2 resistant starch was the form most often studied in a 2022 review of randomized trials.

Category
Other
Forms
High-amylose maize starch (type 2 resistant starch, RS2); cross-linked phosphorylated RS4
Strongest evidence
B Some positive trials
Reviewed
2026-10-30

Class 1 Well studied in people. A 2021 meta-analysis pooled 19 RCTs of resistant starch versus digestible starch, excluding type 1 resistant starch and mixtures with other functional food ingredients. [2]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied3 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Resistant starch does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Resistant starch, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Fasting glucose and insulin resistanceBA 2021 meta-analysis of 19 RCTs (excluding type 1 resistant starch and mixtures) found resistant starch lowered fasting glucose by 0.09 mmol/L and HOMA-IR by 0.33 versus digestible starch; other insulin measures did not change significantly. [2]
Type 2 diabetes riskCFDA concluded there is limited credible evidence for a relationship between high-amylose maize starch (at least 50% RS2) and reduced type 2 diabetes risk; a few studies with mixed surrogate-endpoint results suggested a reduction. [1]
Total and LDL cholesterolBA 2018 meta-analysis of 20 trials (14 articles) found resistant starch lowered total cholesterol by 7.33 mg/dL and LDL cholesterol by 3.40 mg/dL; effects were clearer with supplementation longer than 4 weeks. [3]
Bowel function in healthy adultsBA 2017 meta-analysis of RCTs in healthy adults found resistant starch increased fecal wet weight (35.51 g/day) and butyrate and lowered fecal pH, but did not significantly change defecation frequency. [4]

Main constituents: Type 2 resistant starch (RS2) in high-amylose maize (HAM) starch; FDA's qualified claim covers HAM starch with 50 percent or more RS2 that is unmodified and only conventionally milled [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Studied in trials: most RCTs in a 2022 systematic review used type 2 resistant starch at 20–40 g/day. [5]
  • In the glycemic meta-analysis, the fasting-glucose effect was larger at more than 28 g/day or with interventions longer than 8 weeks. [2]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • A 2022 systematic review of 39 RCTs (2,263 participants) found resistant starch was tolerated in all 11 studies reporting tolerability in people with conditions such as obesity or prediabetes, and in 14 of 20 such studies in healthy people; most used type 2 resistant starch at 20–40 g/day. [5]
  • In one trial FDA reviewed (41 adults with overweight or obesity), one participant withdrew because of constipation while taking high-amylose maize starch providing 30 g/day RS2. [1]
Quality

Identity, quality and standardization

  • Resistant starch content varies: FDA noted that one study did not provide the amount of high-amylose maize starch or RS2 used and another used a starch with only about 33% RS2, below the 50% or more covered by its qualified claim. [1]
Regulation

Regulatory status

  • US: FDA intends to consider exercising enforcement discretion for qualified health claims such as: "High-amylose maize resistant starch may reduce the risk of type 2 diabetes. FDA has concluded that there is limited scientific evidence for this claim." (letter of December 12, 2016). [1]
  • US: FDA lists "high amylose starch (resistant starch 2)" and cross-linked phosphorylated RS4 among non-digestible carbohydrates it intends to propose adding to the dietary fiber definition; meanwhile it intends to exercise enforcement discretion for their declaration as dietary fiber. [6]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Type 2 resistant starch (RS2), e.g. in unmodified high-amylose maize starch Polysaccharides (starch) [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming resistant starch was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
  • FDA letter of enforcement discretion (December 12, 2016): qualified health claims for high-amylose maize resistant starch and type 2 diabetes risk, stating that FDA has concluded there is limited scientific evidence for the claim. [P1]
  • Dietary fiber: FDA lists high amylose starch (resistant starch 2) and cross-linked phosphorylated RS4 among non-digestible carbohydrates it intends to propose as dietary fiber. [P3]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of resistant starch was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P4]
  • The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of resistant starch (checked 2026-10-29). [P5]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P6]
  • RS2 content of high-amylose maize starch (50 percent or more for the qualified claim) — FDA's qualified claim covers only HAM starch with at least 50% RS2, unmodified and conventionally milled; FDA noted studies where RS2 content was unreported or about 33%. [P1]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • Resistant starch is not digested in the small intestine; it is fermented in the colon. In a 2022 systematic review, short-chain fatty acid production rose in 16 of 23 RCTs that measured it; the review reports no change in 7 and a decrease in 1. [P7]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. FDA. Letter of enforcement discretion: Petition for a health claim for high-amylose maize starch (containing type-2 resistant starch) and reduced risk of type 2 diabetes mellitus, Docket FDA-2015-Q-2352 (December 12, 2016), 2016-12-12. fda.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. FDA. Questions and Answers on Dietary Fiber (content current as of 07/25/2024), 2024-07-25. fda.gov
  4. IARC Monographs. List of Classifications, Volumes 1–142 (list data dated 2026-07-23; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
  5. National Toxicology Program (NIEHS). Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  6. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/28/2026), 2026-10-28. ecfr.gov
  7. Sobh M, et al. Tolerability and SCFA production after resistant starch supplementation in humans: a systematic review of randomized controlled studies. Am J Clin Nutr 2022;115(3):608-618 (PMID 34871343), 2022-03. pubmed.ncbi.nlm.nih.gov
Sources

Sources

  1. FDA. Letter of enforcement discretion: Petition for a health claim for high-amylose maize starch (containing type-2 resistant starch) and reduced risk of type 2 diabetes mellitus, Docket FDA-2015-Q-2352 (December 12, 2016), 2016-12-12. fda.gov
  2. Xiong K, et al. Effects of resistant starch on glycaemic control: a systematic review and meta-analysis. Br J Nutr 2021;125(11):1260-1269 (PMID 32959735), 2021-06. pubmed.ncbi.nlm.nih.gov
  3. Yuan HC, et al. Meta-analysis indicates that resistant starch lowers serum total cholesterol and low-density cholesterol. Nutr Res 2018;54:1-11 (PMID 29914662), 2018-06. pubmed.ncbi.nlm.nih.gov
  4. Shen D, et al. Positive effects of resistant starch supplementation on bowel function in healthy adults: a systematic review and meta-analysis of randomized controlled trials. Int J Food Sci Nutr 2017;68(2):149-157 (PMID 27593182), 2017-03. pubmed.ncbi.nlm.nih.gov
  5. Sobh M, et al. Tolerability and SCFA production after resistant starch supplementation in humans: a systematic review of randomized controlled studies. Am J Clin Nutr 2022;115(3):608-618 (PMID 34871343), 2022-03. pubmed.ncbi.nlm.nih.gov
  6. FDA. Questions and Answers on Dietary Fiber (content current as of 07/25/2024), 2024-07-25. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.